secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001711279-26-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111
--------------------------------------------------------------------------------

- Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.
- FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.
- Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.
- Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
- VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/0001711279-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/krys-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer